Efficacy of Silexan in mixed anxiety - depression - A randomized, placebo - controlled trial / Siegfried Kasper en European Neuropsychopharmacology, Año 2016 - Vol. 26 - No.2 (Febrero)

Público ISBD [artículo]  inEuropean Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 331-340 Título : Efficacy of Silexan in mixed anxiety - depression - A randomized, placebo - controlled trial Tipo de documento: texto impreso Autores: Siegfried Kasper, Autor ; Hans Peter Volz, Autor ; Angelika Dienel, Autor Fecha de publicación: 2021 Artículo en la página: pp. 331-340 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Silexan, Lavanda, Ansiedad, Depresión, Ensayo clínico, Eficacia del tratamiento Resumen: Mixed anxiety and depressive disorder (MADD; ICD-10 F41.2) is a condition characterized by subsyndromal symptoms of anxiety and depression, neither of which are clearly predominant. Link: ./index.php?lvl=notice_display&id=26615 [artículo] Efficacy of Silexan in mixed anxiety - depression - A randomized, placebo - controlled trial [texto impreso] / Siegfried Kasper, Autor ; Hans Peter Volz, Autor ; Angelika Dienel, Autor . - 2021 . - pp. 331-340. Idioma : Inglés (eng) Idioma original : Inglés (eng) in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 331-340 Palabras clave: Silexan, Lavanda, Ansiedad, Depresión, Ensayo clínico, Eficacia del tratamiento Resumen: Mixed anxiety and depressive disorder (MADD; ICD-10 F41.2) is a condition characterized by subsyndromal symptoms of anxiety and depression, neither of which are clearly predominant. Link: ./index.php?lvl=notice_display&id=26615

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group / Hans Jürgen Möller en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 59-65 Título : Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group Tipo de documento: texto impreso Autores: Hans Jürgen Möller, Autor ; Hans Peter Volz, Autor ; Ingrid W. Reimann, Autor Fecha de publicación: 2023 Artículo en la página: pp. 59-65 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Alprazolam, Ansiolíticos, Antidepresivos, Trastornos de ansiedad, Opipramol. Resumen: Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were revealed. However, those studies were performed before the concept of generalized anxiety disorder (GAD) was established. Link: ./index.php?lvl=notice_display&id=31138 [artículo] Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group [texto impreso] / Hans Jürgen Möller, Autor ; Hans Peter Volz, Autor ; Ingrid W. Reimann, Autor . - 2023 . - pp. 59-65. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 59-65 Palabras clave: Alprazolam, Ansiolíticos, Antidepresivos, Trastornos de ansiedad, Opipramol. Resumen: Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were revealed. However, those studies were performed before the concept of generalized anxiety disorder (GAD) was established. Link: ./index.php?lvl=notice_display&id=31138

---

1 (1 - 2 / 2)